SOURCE-LINKED STUDY SUMMARY
Testosterone monitoring and supplementation in patients with intermediate- or high-risk prostate cancer treated with 6-36 months of androgen deprivation therapy and radiotherapy: a systematic literature review.
Abstract summarizedQuality not appraised
- What was studied
- A systematic review of testosterone monitoring, recovery and replacement after androgen-deprivation therapy plus radiotherapy for prostate cancer.
- Who / model studied
- Twenty-nine studies concerning intermediate- or high-risk localized prostate cancer. Searches ran through May 2026; total participant numbers are not given in the abstract.
- Studied dose & schedule
- Dose and schedule were not reported in the source used for this summary.
- What the study found
- Baseline testosterone predicted recovery rather than cancer outcomes. Lower testosterone during treatment was associated with better cancer outcomes. Recovery varied, often taking years to normalize, with longer treatment, older age and lower starting testosterone associated with slower recovery.
- Limitations & context
- Evidence about testosterone replacement after curative treatment was very limited and observational, particularly in high-risk patients. It does not establish recurrence safety.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.radonc.2026.111777